Recently, multiple innovative research achievements from Suzhou SmartNuclide Biopharmaceutical have been officially accepted by the 2025 European Association of Nuclear Medicine (EANM) Annual Congress. These works will be presented at the congress through Top Rated Oral Presentations and e-Posters. This not only reflects international peer recognition of SmartNuclide’s scientific research level but also demonstrates the company’s robust capabilities in the field of radiopharmaceutical R&D.

Congress Overview

Dates: October 4 – 8, 2025

Location: Barcelona, Spain

SmartNuclide Presentation Details:

Presentation #1

Presentation Type: Top Rated Oral Presentation

Abstract No.: OP-415

Session: M2M Track – TROP Session – Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Innovations in Translational Oncology

Title: A feasibility study of SmartX platform for a two-step pretargeted radioimmunotherapy (PRIT): taking GD2-expressing neuroblastoma as an example

Date: Monday, October 6, 2025

Time: 15:40 – 15:50

Room: Room 114

Presentation #2

Presentation Type: Top Rated Oral Presentation

Abstract No.: OP-762

Session: M2M Track – TROP Session – Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Antibodies and Co.

Title: Therapeutic potential of first-in-class claudin 18.2-targeted radiolabeled nanobody [¹⁷⁷Lu]Lu-DOTA-SNA014 in gastric cancer

Date: Wednesday, October 8, 2025

Time: 08:20 – 08:30

Room: Room 114

Presentation #3

Presentation Type: e-Poster

Abstract No.: EPS-157

Session: e-Poster Presentations Session 8 – Oncology & Theranostics Committee: Cancer Imaging and Therapy

Title: Two-step pretargeted radioimmunotherapy of GPA33-expressing colorectal cancer with optimized self-assembling and disassembling bispecific fusion protein tetramer

Date: Monday, October 6, 2025

Time: 16:45 – 16:49

Room: Rooms 133 & 134

The EANM Annual Congress is globally recognized as a premier professional meeting in nuclear medicine, representing one of the annual events with the highest technical standards and greatest influence in the field internationally. The 2024 congress brought together over 8,000 nuclear medicine experts, researchers, and industry representatives from Europe and around the world to showcase the latest research achievements. SmartNuclide’s participation at this congress not only highlights the company’s R&D strength but will also further contribute to bringing innovative radiopharmaceuticals from China to the global stage.

We sincerely invite peers, partners, and members of the media to follow SmartNuclide’s presentations at the 2025 EANM Annual Congress. Our team will be present at the congress to engage in in-depth discussions with global experts and scholars, exploring future directions in nuclear medicine. We look forward to your attention and interaction.